Factor V Leiden mutation carriership and @entity1211 in polycythemia vera and XXXX .

@entity1 @entity49 @entity10855 @entity102 @entity74 @entity4407 @entity1211 @entity715
Polycythemia Vera (PV) and @entity4407 ( @entity4407 ) are @entity102 complicated by a high incidence of @entity715 . Extensive coagulation studies failed to demonstrate a consistent pattern of abnormalities associated with @entity715 . Recently, a poor anticoagulant response to @entity10855 ( @entity10855 ), due to a mutation of factor V (FV Leiden), has been identified as the most frequent @entity74 associated with venous @entity49 . We investigated in 304 @entity1 with PV and @entity4407 whether the presence of FV Leiden could be a risk factor for @entity715 . FV Leiden was found in 14/304 @entity1 (4.6%) and was associated with @entity1211 ( @entity1211 ) occurred before and at diagnosis (5/27,16%, with a significant difference of prevalence in comparison of that observed in asymptomatic @entity1 , 9/263, 3%, p = 0.003). Carriership of FV Leiden was associated with @entity1211 relapse, with a prevalence of 3.6% in asymptomatic @entity1 , 6.9% in @entity1 with a single episode of @entity1211 and 18.1% in @entity1 with recurrent @entity1211 . The prevalence of FV Leiden in @entity1 with and without arterial @entity715 was similar (5/79, 6% and 9/211, 4%, respectively, p = 0.337). This study indicates that the prevalence of the FV Leiden mutation in @entity1 with PV and @entity4407 is comparable with that observed in the general population. FV Leiden mutation is a risk factor for @entity1211 before and at time of diagnosis and for @entity1211 recurrences. Screening for FV Leiden may be considered to identify PV and @entity4407 @entity1 at higher risk of recurrences.
